Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Vivozon’s new painkiller completes clinical trial phase 2a in US
By 황유미Published : Sept. 7, 2016 - 17:10
[THE INVESTOR] Vivozon’s VVZ-149, a nonopioid analgesics, has completed the 2a phase of clinical trials in the US, according to its largest stakeholder Telcon on Sept. 7.
The drug development venture was established in 2008 and its painkiller candidate is currently under phase 2b of clinical trials in the country. In the US the company has finished preparation for the phase 2b.
Telcon and its subsidiary KPM Tech will further increase their stakes in Vivozon and seek to diversify into biopharmaceutical business.
By Hwang You-mee (glamazon@heraldcorp.com)
The drug development venture was established in 2008 and its painkiller candidate is currently under phase 2b of clinical trials in the country. In the US the company has finished preparation for the phase 2b.
Telcon and its subsidiary KPM Tech will further increase their stakes in Vivozon and seek to diversify into biopharmaceutical business.
By Hwang You-mee (glamazon@heraldcorp.com)
